Cargando…

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib

Cabozantinib (XL-184) is a multitarget tyrosine kinase inhibitor (TKI) targeting receptor tyrosine kinases (RTKs) involved in oncogenesis and angiogenesis. It is currently the standard therapy for medullary thyroid cancer (MTC), metastatic renal cell carcinoma (mRCC), and hepatocellular carcinoma (H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scirocchi, Fabio, Napoletano, Chiara, Pace, Angelica, Rahimi Koshkaki, Hassan, Di Filippo, Alessandra, Zizzari, Ilaria Grazia, Nuti, Marianna, Rughetti, Aurelia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564482/ https://www.ncbi.nlm.nih.gov/pubmed/34745989 http://dx.doi.org/10.3389/fonc.2021.755433

Ejemplares similares

Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis
por: Scirocchi, Fabio, et al.
Publicado: (2022)

Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma
por: Pace, Angelica, et al.
Publicado: (2022)

Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs
por: Pace, Angelica, et al.
Publicado: (2023)

Immune effects of CDK4/6 inhibitors in patients with HR(+)/HER2(−) metastatic breast cancer: Relief from immunosuppression is associated with clinical response
por: Scirocchi, Fabio, et al.
Publicado: (2022)

Circulating CD137(+) T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients
por: Cirillo, Alessio, et al.
Publicado: (2023)

The Macrophage Galactose-Type C-Type Lectin (MGL) Modulates Regulatory T Cell Functions
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2015)

MGL Receptor and Immunity: When the Ligand Can Make the Difference
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2015)

The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study
por: Botticelli, Andrea, et al.
Publicado: (2021)

Tumor-Derived Microvesicles Modulate Antigen Cross-Processing via Reactive Oxygen Species-Mediated Alkalinization of Phagosomal Compartment in Dendritic Cells
por: Battisti, Federico, et al.
Publicado: (2017)

Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2020)

Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity
por: Ceccarelli, Fulvia, et al.
Publicado: (2023)

Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells
por: Dionisi, Marco, et al.
Publicado: (2018)

Immunohistochemical Characterization of Immune Infiltrate in Tumor Microenvironment of Glioblastoma
por: Rahimi Koshkaki, Hassan, et al.
Publicado: (2020)

HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2011)

Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets
por: Napoletano, Chiara, et al.
Publicado: (2019)

Immune Effects of Trastuzumab
por: Nuti, Marianna, et al.
Publicado: (2011)

Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View
por: Bellati, Filippo, et al.
Publicado: (2011)

Tumor associated MUC1 carried by microvesicles is cross-processed by dendritic cells generating CD8+ T cell response
por: Zizzari, Ilaria G, et al.
Publicado: (2013)

Preliminary results of a triple peptide escalating dose vaccination phase I/II clinical trial as consolidation treatment in women affected by ovarian cancer
por: Napoletano, Chiara, et al.
Publicado: (2013)

Circulating CD137(+) T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2022)

Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial
por: ANTONILLI, MORENA, et al.
Publicado: (2016)

Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2020)

Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-Type Lectin (MGL)
por: Napoletano, Chiara, et al.
Publicado: (2020)

IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137(+)T-cells
por: Ugolini, Alessio, et al.
Publicado: (2020)

A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors
por: Mezi, Silvia, et al.
Publicado: (2023)

Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach
por: Botticelli, Andrea, et al.
Publicado: (2023)

Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression
por: Napoletano, Chiara, et al.
Publicado: (2010)

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment
por: Botticelli, Andrea, et al.
Publicado: (2016)

Proteomic characterization of extracellular vesicles released by third stage larvae of the zoonotic parasite Anisakis pegreffii (Nematoda: Anisakidae)
por: Palomba, Marialetizia, et al.
Publicado: (2023)

Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms
por: Cella, Chiara Alessandra, et al.
Publicado: (2023)

Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells
por: Matsushita, Maiko, et al.
Publicado: (2023)

Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
por: Davda, Jasmine, et al.
Publicado: (2019)

Therapeutic Implications of Immunogenic Cell Death in Human Cancer
por: Palombo, Fabio, et al.
Publicado: (2014)

Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study
por: Rossi, Ernesto, et al.
Publicado: (2022)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Cabozantinib‐induced renal thrombotic microangiopathy
por: La Manna, Gaetano, et al.
Publicado: (2017)

Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019)

Corrigendum to “Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring”
por: Macchia, Iole, et al.
Publicado: (2020)

Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring
por: Macchia, Iole, et al.
Publicado: (2020)

Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions
por: Fioramonti, Marco, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_520q4d4hblsim01mrf2kk9dsq6